These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 15848570

  • 1. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
    Tan J, Yang S, Wu W.
    Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids.
    Turconi A, Rilo LR, Goldberg J, de Boccardo G, Garsd A, Otero A.
    Transplant Proc; 2005 Mar; 37(2):672-4. PubMed ID: 15848497
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Basiliximab (Simulect) in acute tubular necrosis high-risk kidney transplantation.
    Rivera CF, Hernández AA, Verdejo PV, García JO, Rego SC, Cañedo FV.
    Transplant Proc; 2005 Nov; 37(9):3733-5. PubMed ID: 16386521
    [Abstract] [Full Text] [Related]

  • 6. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.
    Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ, Troisi R, Jacobs B, Van Vlem B, de Hemptinne B, Van Holder R, Vermassen F, De Roose J, Lameire N.
    Clin Transplant; 2000 Aug 27; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [Abstract] [Full Text] [Related]

  • 9. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
    Thistlethwaite JR, Nashan B, Hall M, Chodoff L, Lin TH.
    Transplantation; 2000 Sep 15; 70(5):784-90. PubMed ID: 11003358
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, Kahn D, Kashi H, Salmela K, Fricke L, Heemann U, Garcia-Martinez J, Lechler R, Prestele H, Girault D, Simulect Phase IV Study Group.
    Transplantation; 2001 Oct 15; 72(7):1261-7. PubMed ID: 11602853
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun 15; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 14. Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function.
    Fernandez Rivera C, Alonso Hernandez A, Villaverde Verdejo P, Oliver García J, Valdés Cañedo F.
    Transplant Proc; 2005 Apr 15; 37(3):1435-7. PubMed ID: 15866629
    [Abstract] [Full Text] [Related]

  • 15. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD, Rajagopalan PR, Hall M.
    Transplantation; 1999 Jan 27; 67(2):276-84. PubMed ID: 10075594
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D, Kotnik V, Kandus A.
    Transplant Proc; 2005 Dec 27; 37(10):4230-4. PubMed ID: 16387086
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.